Apexigen

Please note: The information displayed on this page might be outdated.
Apexigen: CD40 targeting immune checkpoint activators. 400+ patients dosed; efficacy in neoadjuvant, 1L and post-PD-1/PD-L1 settings, in both PD-1(+) and (-) pts and mult tumor types. Lead molecule APX005M: >400 pts enrolled across 13 trials; efficacy in 3 cancer indications, multiple settings. APXiMAB™ robust Ab discovery platform, licensing partnerships. BLA approval for 1st APXiMAB licensed product in 2019 validates platform, receiving royalties
Proprietary pipeline: APX601 (anti-TNFR2) & anti-SIRPα IND candidates. $125M March 2020 Series C (Decheng, Oceanpine, 3E, Virtus, SV Tech, et al)
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Phase III
Disease Space
Autoimmune, Immuno-Oncology, Oncology
Listing
Private
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
75 Shoreway Road
Suite C
San Carlos, CA 94070
United States

Company Participants at Private Company Showcase NYC 2019

  • Linda Rubinstein, Interim Chief Financial Officer
  • Xiaodong Yang, PhD, Founder, President & Chief Executive Officer